APA (7th ed.) Citation

Nicola Ferrante, Daniela Ritrovato, Rossella Bitonti, & Gianluca Furneri. (2022). Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy. BMC.

Chicago Style (17th ed.) Citation

Nicola Ferrante, Daniela Ritrovato, Rossella Bitonti, and Gianluca Furneri. Cost-effectiveness Analysis of Brolucizumab Versus Aflibercept for the Treatment of Neovascular Age-related Macular Degeneration (nAMD) in Italy. BMC, 2022.

MLA (9th ed.) Citation

Nicola Ferrante, et al. Cost-effectiveness Analysis of Brolucizumab Versus Aflibercept for the Treatment of Neovascular Age-related Macular Degeneration (nAMD) in Italy. BMC, 2022.